Spero Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|
| Revenue | $4.0M | $2.0M | $335.0K | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $33.9M | $32.9M | $26.3M | $11.1M |
| SG&A Expense | $12.9M | $10.8M | $7.2M | $2.2M |
| Operating Income | $-42.8M | $-41.7M | $-33.2M | $-13.3M |
| Operating Margin | -1,079.3% | -2,108.6% | -9,916.7% | — |
| Interest Expense | — | — | — | — |
| Pretax Income | $-41.7M | $-39.9M | $-32.6M | $-13.2M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $-41.7M | $-38.7M | $-25.5M | $-10.2M |
| Net Margin | -1,051.4% | -1,957.7% | -7,609.3% | — |
| EPS (Basic) | $-2.60 | $-17.82 | $-95.87 | $-53.11 |
| EPS (Diluted) | $-2.60 | $-17.82 | $-95.87 | $-53.11 |
| Shares Outstanding (Basic) | 17.2M | 14.4M | 0 | — |
| Shares Outstanding (Diluted) | 17.2M | 14.4M | 0 | — |
| Dividends Per Share | — | — | — | — |